This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Y. Wang, S. Zou, Z. Zhao, P. Liu, C. Ke and S. Xu, New insights into small-cell lung cancer development and therapy, Cell Biol. Int. 44(8) (2020) 1564–1576; https://doi.org/10.1002/cbin.11359Search in Google Scholar
A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte and L. Bonanno, Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges, J. Immunother. Cancer7(1) (2019) Article ID 205 (13 pages); https://doi.org/10.1186/s40425-019-0690-1Search in Google Scholar
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 68(6) (2018) 394–424; https://doi.org/10.3322/caac.21492Search in Google Scholar
H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660Search in Google Scholar
P. Goldstraw, Updated staging system for lung cancer, Surg. Oncol. Clin. N. Am. 20(4) (2011) 655–666; https://doi.org/10.1016/j.soc.2011.07.005Search in Google Scholar
G. P. Kalemkerian, Small cell lung cancer, Semin. Respir. Crit. Care Med. 37(5) (2016) 783–796; https://doi.org/10.1055/s-0036-1592116Search in Google Scholar
E. B. Bernhardt and S. I. Jalal, Small cell lung cancer, Cancer Treat. Res. 170 (2016) 301–322; https://doi.org/10.1007/978-3-319-40389-2_14Search in Google Scholar
G. P. Kalemkerian and B. J. Schneider, Advances in small cell lung cancer, Hematol. Oncol. Clin. North Am. 31(1) (2017) 143–156; https://doi.org/10.1016/j.hoc.2016.08.005Search in Google Scholar
S. Sundstrom, R. M. Bremnes, S. Kaasa, U. Aasebo, R. Hatlevoll, R. Dahle, N. Boye, M. Wang, T. Vigander, J. Vilsvik, E. Skovlund, E. Hannisdal, S. Aamdal and G. Norwegian, Lung cancer study: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up, J. Clin. Oncol. 20(24) (2002) 4665–4672; https://doi.org/10.1200/JCO.2002.12.111Search in Google Scholar
M. Takada, M. Fukuoka, M. Kawahara, T. Sugiura, A. Yokoyama, S. Yokota, Y. Nishiwaki, K. Watanabe, K. Noda, T. Tamura, H. Fukuda and N. Saijo, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J. Clin. Oncol. 20(14) (2002) 3054–3060; https://doi.org/10.1200/JCO.2002.12.071Search in Google Scholar
R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, Cancer statistics, 2021, C. A. Cancer J. Clin. 71(1) (2021) 7–33; https://doi.org/10.3322/caac.21654Search in Google Scholar
G. S. Jones and D. R. Baldwin, Recent advances in the management of lung cancer, Clin. Med. (Lond). 18(Suppl 2) (2018) s41-s46; https://doi.org/10.7861/clinmedicine.18-2-s41Search in Google Scholar
C. Ma, J. Tang, H. Wang, G. Tao, X. Gu and L. Hu, Preparative purification of salidroside from Rhodiola rosea by two-step adsorption chromatography on resins, J. Sep. Sci. 32(2) (2009) 185–191; https://doi.org/10.1002/jssc.200800438Search in Google Scholar
A. Kucinskaite, V. Briedis and A. Savickas, Experimental analysis of therapeutic properties of Rhodiola rosea L. and its possible application in medicine, Medicina (Kaunas)40(7) (2004) 614–619.Search in Google Scholar
Y. Li, J. Wu, R. Shi, N. Li, Z. Xu and M. Sun, Antioxidative effects of Rhodiola genus: Phytochemistry and pharmacological mechanisms against the diseases, Curr. Top. Med. Chem. 17(15) (2017) 1692–1708; https://doi.org/10.2174/1568026617666161116141334Search in Google Scholar
S. N. Udintsev and V. P. Shakhov, Decrease in the growth rate of Ehrlich’s tumor and Pliss’ lymphosarcoma with partial hepatectomy, Vopr. Onkol. 35(9) (1989) 1072–1075.Search in Google Scholar
H. Zhang, C. Ding, Y. Li, C. Xing, S. Wang, Z. Yu, L. Chen, P. Li and M. Dai, Data mining-based study of collagen type III alpha 1 (COL3A1) prognostic value and immune exploration in pan-cancer, Bioengineered12(1) (2021) 3634–3646; https://doi.org/10.1080/21655979.2021.1949838Search in Google Scholar
X. Xin, D. Yao, K. Zhang, S. Han, D. Liu, H. Wang, X. Liu, G. Li, J. Huang and J. Wang, Protective effects of rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice, Biomed. Pharmacother. 115 (2019) Article ID 108870 (8 pages); https://doi.org/10.1016/j.biopha.2019.108870Search in Google Scholar
W. X. Peng, J. G. Huang, L. Yang, A. H. Gong and Y. Y. Mo, Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer, Mol. Cancer16(1) (2017) Article ID 161 (11 pages); https://doi.org/10.1186/s12943-017-0727-3Search in Google Scholar
M. Pashirzad, R. Khorasanian, M. M. Fard, M. H. Arjmand, H. Langari, M. Khazaei, S. Soleiman-pour, M. Rezayi, G. A. Ferns, S. M. Hassanian and A. Avan, The therapeutic potential of MAPK/ERK inhibitors in the treatment of colorectal cancer, Curr. Cancer Drug Targets21(11) (2021) 932–943; https://doi.org/10.2174/1568009621666211103113339Search in Google Scholar
B. Wang, X. X. Zhu, L. Y. Pan, H. F. Chen and X. Y. Shen, PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway, Pathol. Res. Pract. 216(5) (2020) Article ID 152910; https://doi.org/10.1016/j.prp.2020.152910Search in Google Scholar
Z. Wang, G. Kan, C. Sheng, C. Yao, Y. Mao and S. Chen, ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer, Biochem. Biophys. Res. Commun. 533(4) (2020) 792–799; https://doi.org/10.1016/j.bbrc.2020.09.085Search in Google Scholar
Y. Liu, Z. Zhang, T. Song, F. Liang, M. Xie and H. Sheng, Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2, Br. J. Pharmacol. 169(7) (2013) 1612–1623; https://doi.org/10.1111/bph.12243Search in Google Scholar
S. Cristea and J. Sage, Is the canonical RAF/MEK/ERK signaling pathway a therapeutic target in SCLC?, J. Thorac. Oncol. 11(8) (2016) 1233–1241; https://doi.org/10.1016/j.jtho.2016.04.018Search in Google Scholar
A. S. Marchev, P. Dimitrova, I. K. Koycheva and M. I. Georgiev, Altered expression of TRAIL on mouse T cells via ERK phosphorylation by Rhodiola rosea L. and its marker compounds, Food Chem. Toxicol. 108(Pt B) (2017) 419–428; https://doi.org/10.1016/j.fct.2017.02.009Search in Google Scholar
R. Ruiz-Cordero and W. P. Devine, Targeted therapy and checkpoint immunotherapy in lung cancer, Surg. Pathol. Clin. 13(1) (2020) 17–33; https://doi.org/10.1016/j.path.2019.11.002Search in Google Scholar
E. C. Naylor, J. K. Desani and P. K. Chung, Targeted therapy and immunotherapy for lung cancer, Surg. Oncol. Clin. N. Am. 25(3) (2016) 601–609; https://doi.org/10.1016/j.soc.2016.02.011Search in Google Scholar
R. M. Montiel-Ruiz, M. E. Gonzalez-Trujano and M. Deciga-Campos, Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test, Phytomedicine20(14) (2013) 1280–1287; https://doi.org/10.1016/j.phymed.2013.07.006Search in Google Scholar
M. Deciga-Campos, M. E. Gonzalez-Trujano, R. Ventura-Martinez, R. M. Montiel-Ruiz, G. E. Angeles-Lopez and F. Brindis, Antihyperalgesic activity of Rhodiola rosea in a diabetic rat model, Drug Dev. Res. 77(1) (2016) 29–36; https://doi.org/10.1002/ddr.21289Search in Google Scholar
Z. Liu, X. Li, A. R. Simoneau, M. Jafari and X. Zi, Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of auto-phagy, Mol. Carcinog. 51(3) (2012) 257–267; https://doi.org/10.1002/mc.20780Search in Google Scholar
A. Majewska, G. Hoser, M. Furmanowa, N. Urbanska, A. Pietrosiuk, A. Zobel and M. Kuras, Anti-proliferative and antimitotic effect, S phase accumulation and induction of apoptosis and necrosis after treatment of extract from Rhodiola rosea rhizomes on HL-60 cells, J. Ethnopharmacol. 103(1) (2006) 43–52; https://doi.org/10.1016/j.jep.2005.05.051Search in Google Scholar
X. Hu, S. Lin, D. Yu, S. Qiu, X. Zhang and R. Mei, A preliminary study: the anti-proliferation effect of salidroside on different human cancer cell lines, Cell Biol. Toxicol. 26(6) (2010) 499–507; https://doi.org/10.1007/s10565-010-9159-1Search in Google Scholar
W. Zhang, W. Zhang, L. Huo, Y. Chai, Z. Liu, Z. Ren and C. Yu, Rosavin suppresses osteoclasto-genesis in vivo and in vitro by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways, Ann. Transl. Med. 9(5) (2021) Article ID 383 (14 pages); https://doi.org/10.21037/atm-20-4255Search in Google Scholar